Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
06:02pm, Monday, 19'th Sep 2022 Benzinga
HC Wainwright is assuming coverage on AnaptysBio Inc (NASDAQ: ANAB) with a Buy Rating and a price target of $35 at a unique inflection point since it was founded in 2005.
The company's lead ass
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle
03:14pm, Tuesday, 13'th Sep 2022 Benzinga
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday.
Truist Securities cut the price target on A
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
02:13pm, Tuesday, 13'th Sep 2022 Benzinga
Upgrades
See all analyst ratings upgrades.
Downgrades
Argus Research downgraded the previous rating for Tyson Foods Inc (NYSE:TSN) from Buy to Hold. In the third quarter, Tyson Foods showed an EPS of
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
05:41pm, Friday, 02'nd Sep 2022 Benzinga
Raymond James initiated coverage on AnaptysBio Inc (NASDAQ: ANAB) with an Outperform rating and a $35 price target.
The analyst has a positive outlook on the lead asset imsidolimab in generalized
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
02:33pm, Thursday, 01'st Sep 2022 Benzinga
Upgrades
For iQIYI Inc (NASDAQ:IQ), UBS upgraded the previous rating of Neutral to Buy. For the second quarter, iQIYI had an EPS of $0.01, compared to year-ago quarter EPS of $0.27. At the moment, the
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
08:15pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced top-lin
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
09:35pm, Monday, 08'th Aug 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
08:00pm, Friday, 05'th Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Da
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
04:00pm, Friday, 05'th Aug 2022
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan
Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?
11:22am, Friday, 08'th Jul 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
08:05pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanism
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
10:55pm, Wednesday, 04'th May 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
08:15pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
